Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized stron...
Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
Although the S&P 500 is down 2.8% over the past six months, Danaher’s stock price has fallen further to $190.75, losing shareholders 9.3% of their capital. T...
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Danaher (NYSE:DHR) and its peers. Th...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making
As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry bellwethers, once buoyed by post-pandemic expansion and aggressive R&D spending, are now issuing sober forecast revisions that reflect a
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
WALTHAM, MA — In a market defined by shifting geopolitical alliances and a renewed "flight to quality," Thermo Fisher Scientific (NYSE:TMO) has once again asserted its dominance as the bedrock of the life sciences sector. Reporting its fourth-quarter 2025 results on January 29, 2026, the company delivered a robust earnings
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire Penumbra, Inc. (NYSE:PEN) for an enterprise value of approximately $14.5 billion. This transaction, structured as a mix of 73% cash
In a move that has sent shockwaves through the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for $180.00 per share in an all-cash transaction. The deal, valued at approximately $9.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
In a move that signals a massive consolidation in the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion. The all-cash deal, valued at $180 per share, represents
As of February 17, 2026, Danaher Corporation (NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]
The deal will entail Danaher paying $180 per share for Masimo, reflecting about 18 times Masimo’s projected 2027 earnings before interest, taxes, depreciation, and amortization.
On February 11, 2026, the global water technology leader Xylem Inc (NYSE: XYL) finds itself at a critical crossroads. Following the release of its full-year 2025 earnings report just yesterday, the market has reacted with a complex mixture of admiration and apprehension. While Xylem achieved record-breaking revenue and successfully integrated its massive $7.5 billion Evoqua [...]
As of February 10, 2026, Waters Corporation (NYSE: WAT) stands at the most significant crossroads in its nearly 70-year history. Long regarded as the gold standard in liquid chromatography and mass spectrometry, the Milford, Massachusetts-based company has recently transitioned from a specialized toolmaker into a multi-disciplinary life sciences juggernaut. With the closing of its massive [...]
As of February 5, 2026, Fortive Corp (NYSE: FTV) finds itself at a pivotal crossroads. Long known as the "industrial-tech compounder" born from the Danaher heritage, the company has recently completed a massive structural transformation. Following the 2025 spin-off of its Precision Technologies segment into a standalone entity called Ralliant Corporation, the "New Fortive" has [...]
Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging frontiers of cell and gene therapy (CGT), the ability to store, manage, and analyze biological samples with absolute precision is no longer a luxury—it [...]
